GERON CORP Long-Term Debt, Maturity, Remainder of Fiscal Year
GERON CORP (GERN) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $9.02 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-05
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $9.02M.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $11.93M.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $6.42M.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $9.59M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $9.02M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.93M 10-Q · filed 2026-05-06 |
| 2025-09-30 | $6.42M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $9.59M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $12.75M 10-Q · filed 2025-05-07 |
| 2024-09-30 | $2.55M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $5.29M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $53.56M 10-Q · filed 2024-05-02 |
| 2023-09-30 | $1.80M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $3.56M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $5.24M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $1.50M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $2.65M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.53M 10-Q · filed 2022-05-09 |
| 2021-09-30 | $796.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.57M 10-Q · filed 2021-08-16 |
| 2020-09-30 | $388.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |